Background: Metabolic risk factors can impact sarcopenia, but the direct relationship of metabolic risk factors with sarcopenia has not been examined. Our purpose was to investigate the effects of metabolic risk factors on sarcopenia in older adults. Methods: Sixteen studies were found through a search of electronic databases and were subjected to a metaanalysis to investigate the differences in metabolic risk factors between patients with sarcopenia and controls. The random-effects standardized mean difference ±95% confidence interval was calculated as the effect size.
INTRODUCTION
The World Health Organization has reported that the global population of people older than the age of 65 years will reach at least 2 billion by 2050. 1 The aging process can lead to sarcopenia, metabolic diseases, and other chronic diseases. According to the latest annual report on causes of death in the elderly in Korea, the number of patients with sarcopenia is rapidly increasing among those older than 65 years. Sarcopenia is considered to be a common cause of mortality in this age group. 2 In particular, sarcopenia has an increasing impact on the elderly, including incidence With the increase of the global elderly population, sarcopenia will be increasingly common. 11 Sarcopenia is prone to increase the mortality rate of the elderly since it can increase the risk of metabolic diseases. 12 Metabolic diseases refer to clinical syndromes in which risk factors for multiple cardiovascular diseases such as obesity, hypertension, hyperglycemia, dyslipidemia, and the like coexist in an individual. Insulin resistance is the basis of this clinical syndrome. Recent studies reported that decreased skeletal muscle mass increases insulin resistance in vivo, which is closely related to the occurrence of metabolic diseases. 13, 14 For these reasons, increasing body mass can improve insulin sensitivity. 15 In addition, sarcopenia results in atherosclerosis and triggers high blood pressure. 16 With aging, body composition changes, loss of skeletal muscle, and/or increased fat mass may increase the risk of functional impairment and chronic metabolic disease.
Therefore, we performed a meta-analysis of the literature to determine the relationship between sarcopenia and possible metabolic risk factors. The objective of this study was to identify early-stage metabolic risk factors for sarcopenia. The results of this study should support instrumental suggestions for medical institutions and convalescent organizations to carry out corresponding preventive nutrition interventions to reduce the occurrence of metabolic diseases as early as possible.
METHODS
Although a meta-analysis is not a primary research method, it does include steps such as formulation of a problem, collection of data (studies), coding of data, and data analysis and interpretation. 
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Search strategy
Study selection
We included studies that (1) compared data on metabolic risk factors between participants with sarcopenia versus those without, (2) reported on metabolic risk factors such as BMI, fasting glucose, SBP, DBP, triglycerides (TG), HOMA-IR, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and total cholesterol, and (3) separated the data from men and women. Studies were excluded if they (1) did not measure or did not report metabolic risk factors in both sarcopenia and no sarcopenia subjects, (2) examined subjects younger than 65 years or used animal models, or (3) did not measure or report metabolic risk factors both in patients with and without sarcopenia.
Data extraction
Two authors (YD, JK No) independently extracted data from the selected studies into a standardized Microsoft Excel spreadsheet.
Any disagreement was resolved by consensus. The following information was extracted: (1) study population characteristics (e.g., sample size, demographic), (2) survey site at which the study was performed, (3) parameters related to metabolic risk factors in individuals with sarcopenia versus no sarcopenia, and (4) compared data from men and women separately from the overall population. 
Quality assessment
In meta-analyses, the "file drawer problem" refers to unknown, unpublished research whose results fail to confirm the pattern revealed by the published findings. 19 If no unpublished research is retrieved, a publication bias can exist in favor of significant findings, which could distort the results of the meta-analysis. Cooper 20 developed a method for determining the magnitude of the file drawer problem: calculating the minimum number of unpublished studies reporting not significant findings that would be necessary to overturn the conclusion reached in a particular meta-analysis. This number has been defined as the fail-safe number (Nfs). 20 Rosenthal and Hall 21 have proposed that a reasonable tolerance level of the file drawer problem has been achieved if the Nfs exceeds 5n+10 (n, number of studies included in the meta-analysis).
Statistical analysis
The meta-analysis was performed using comprehensive metaanalysis V2.0 for Windows (https://www.meta-analysis.com/).
Only outcomes from at least two studies can be subjected to metaanalysis, while outcomes from only one study were reported in the descriptive analyses. When combining studies, the random effects model was used to account for study heterogeneity 22 by utilizing the standardized mean difference with its 95% confidence interval (CI). Study heterogeneity was measured using the chi-square and I-square statistics, with chi-square P ≤ 0.05 and I-square ≥ 50% indicating the presence of crucial heterogeneity. Publication bias was assessed with a visual inspection of funnel plots and the Egger bias test 23 for outcomes within these metabolic risk factors. Furthermore, this study also utilized Nfs to verify the reliability of the researched nine metabolic risk factors. These factors were used for subgroup analysis based on the analysis of included studies, and the subgroup analysis compared men and women.
RESULTS
The search identified 991 potentially eligible studies, of which 384 duplicates were excluded. After excluding 547 papers through title and abstract review, 60 full-text articles were examined. After further examination, 16 studies were included in the meta-analysis ( Fig. 1 ).
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Study and patient characteristics
Study and patient characteristics are summarized in Table 1 
Effect sizes
After data from the accepted 16 studies were pooled, all nine metabolic risk factors of interest were found to have a significant relationship with sarcopenia (Table 2) 
Subgroup analysis
The results of the random-effects categorical analysis by male and female subgroups are illustrated in Table 3 . The results for the relationship of sarcopenia with metabolic risk factors in men and women were as follows: (1) the effect sizes of all of the male groups were higher than those of the female groups; (2) however, only the effect size of HOMA-IR (P< 0.01) was significant, while the differences of the effect sizes between men and women within each of the other eight risk factor subgroups, namely BMI, fasting glucose, SBP, DBP, TG, HDL-C, LDL-C, and total cholesterol, were not.
Reliability test
The Nfs computed for this meta-analysis regarding the effects of BMI, fasting glucose, SBP, DBP, TG, HOMA-IR, HDL-C, LDL-C, and total cholesterol on sarcopenia were 5,668, 740, 608, 14,903, 9,786, 2,628, 5,915, 21, and 642 unpublished studies, respectively (Table 2) . Only in the case of LDL-C were the Nfs not exceeded, with 45 unpublished studies; therefore, it is difficult to support the effect size.
Publication bias
Publication bias was evaluated to examine the validity of the results of this study. The effect size of the included studies was not visually symmetrical in the funnel plot, which is illustrated in Fig. 3 .
An Egger linear regression test inferred the severity of the publication bias. 40 As a result, we added no new studies to convert the effect size of the included studies from asymmetry to symmetry.
Therefore, the pooled effect size did not convert. To sum up, we could not ensure that the included studies had no publication bias;
however, there was also no evidence to call the validity of the results into question. Indicates a significant effect (P< 0.01); **Indicates fixed-effects. CI, confidence interval; BMI, body mass index; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TG, triglycerides. Finally, the studies did not adjust for any confounding variables, which may have affected both the exposure and outcome. 47 Thus, adjusting for confounders is a good way to reduce potential bias.
According to previous studies, sex can affect the correlation between metabolic risk factors and elder sarcopenia. 41, 46 Therefore, when we accumulate more results, we will perform a subgroup analysis. Moreover, our present subgroup analysis suggests that male sex plays an important role in explaining the association between metabolic risk factors and sarcopenia. This finding seems to be consistent with the current literature suggesting that men have higher metabolic risk factor levels compared with women. These findings suggest that, in the future, sarcopenia-preventive treatments should be sex specific. There are actually relatively few data directly addressing many of these points, all of which are important areas for future research.
This meta-analysis has several limitations. First, the number of included studies was insufficient. Second, while weight loss was not the objective in any of the included studies, we did not control for weight change among participants. Third, according to the criteria of the subgroup analysis, the study can be further refined if there are more heterogeneous samples. Last, ecological fallacy is a possibility as we did not have access to the raw data from the included studies, and we should therefore be cautious interpreting the group results as individual effects. Despite these limitations, to our knowledge, this is the first study to confirm the relationship between metabolic risk factors in sarcopenia in the elderly. We performed a comprehensive literature search using seven electronic databases.
We performed moderation analysis on all variables, with sufficient data provided in the published material. Our research provides evidence for more effective and appropriate early preventive interventions and strategies to reduce the risk of metabolic diseases in the elderly. In the future, we will use a predictive model to calculate effect sizes for each significant moderator and transform that effect size into clinical units of measure for sarcopenia.
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